Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Atrion Co. stock logo
ATRI
Atrion
$459.92
$459.06
$274.98
$503.24
$809.46M0.6923,283 shsN/A
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
$20.00
$19.98
$12.26
$20.57
$843.96M0.74765,906 shs4,300 shs
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
$1.52
-4.7%
$1.91
$1.42
$13.44
$55.55M1.84571,654 shs197,597 shs
Pulmonx Co. stock logo
LUNG
Pulmonx
$5.27
-3.0%
$7.22
$4.89
$10.01
$209.53M0.61324,924 shs116,300 shs
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Atrion Co. stock logo
ATRI
Atrion
0.00%0.00%0.00%0.00%+4.12%
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
0.00%0.00%0.00%0.00%0.00%
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
+8.90%-4.22%-18.46%-23.92%-86.33%
Pulmonx Co. stock logo
LUNG
Pulmonx
-5.07%-20.38%-24.79%-16.33%-37.23%
Remove Ads
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Atrion Co. stock logo
ATRI
Atrion
N/AN/AN/AN/AN/AN/AN/AN/A
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
N/AN/AN/AN/AN/AN/AN/AN/A
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
3.7319 of 5 stars
3.32.00.04.32.60.01.3
Pulmonx Co. stock logo
LUNG
Pulmonx
2.4301 of 5 stars
3.45.00.00.00.02.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Atrion Co. stock logo
ATRI
Atrion
0.00
N/AN/AN/A
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
0.00
N/AN/AN/A
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
2.60
Moderate Buy$12.20705.28% Upside
Pulmonx Co. stock logo
LUNG
Pulmonx
2.75
Moderate Buy$12.75142.17% Upside

Current Analyst Ratings Breakdown

Latest ATRI, CSII, LUNG, and INO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/19/2025
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Perform ➝ Sector Perform$6.00 ➝ $5.00
3/19/2025
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$3.00 ➝ $3.00
3/10/2025
Pulmonx Co. stock logo
LUNG
Pulmonx
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy
3/10/2025
Pulmonx Co. stock logo
LUNG
Pulmonx
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageEqual Weight ➝ Equal Weight
3/10/2025
Pulmonx Co. stock logo
LUNG
Pulmonx
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral ➝ Buy
3/10/2025
Pulmonx Co. stock logo
LUNG
Pulmonx
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy ➝ Buy$17.00 ➝ $17.00
1/13/2025
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$5.00 ➝ $3.00
1/10/2025
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$18.00 ➝ $18.00
(Data available from 4/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Atrion Co. stock logo
ATRI
Atrion
$181.60M4.46$19.68 per share23.37$138.02 per share3.33
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
$239.84M3.52N/AN/A$6.12 per share3.27
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
$217.76K255.10N/AN/A$5.16 per share0.29
Pulmonx Co. stock logo
LUNG
Pulmonx
$83.79M2.50N/AN/A$3.09 per share1.70
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Atrion Co. stock logo
ATRI
Atrion
$19.41M$10.6443.23N/A10.60%7.75%7.12%N/A
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
-$36.93M-$0.97N/AN/AN/A-15.79%-15.39%-11.93%N/A
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
-$135.12M-$3.99N/AN/AN/AN/A-118.17%-83.47%5/12/2025 (Estimated)
Pulmonx Co. stock logo
LUNG
Pulmonx
-$60.84M-$1.44N/AN/AN/A-67.31%-55.36%-33.53%4/29/2025 (Estimated)

Latest ATRI, CSII, LUNG, and INO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2025Q1 2025
Pulmonx Co. stock logo
LUNG
Pulmonx
-$0.37N/AN/AN/A$22.03 millionN/A
3/18/2025Q4 2024
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
-$0.87-$0.69+$0.18-$0.60$0.03 million$0.12 million
2/19/2025Q4 2024
Pulmonx Co. stock logo
LUNG
Pulmonx
-$0.45-$0.33+$0.12-$0.33$22.29 million$23.77 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Atrion Co. stock logo
ATRI
Atrion
$8.801.91%+9.65%82.71%21 Years
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
N/AN/AN/AN/AN/A
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
N/AN/AN/AN/AN/A
Pulmonx Co. stock logo
LUNG
Pulmonx
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Atrion Co. stock logo
ATRI
Atrion
N/A
9.18
3.06
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
0.08
6.04
4.92
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
N/A
3.88
3.88
Pulmonx Co. stock logo
LUNG
Pulmonx
0.40
7.70
6.77

Institutional Ownership

CompanyInstitutional Ownership
Atrion Co. stock logo
ATRI
Atrion
66.19%
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
86.61%
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
26.79%
Pulmonx Co. stock logo
LUNG
Pulmonx
91.04%

Insider Ownership

CompanyInsider Ownership
Atrion Co. stock logo
ATRI
Atrion
22.82%
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
3.80%
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
2.50%
Pulmonx Co. stock logo
LUNG
Pulmonx
5.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Atrion Co. stock logo
ATRI
Atrion
7201.76 million1.36 millionNot Optionable
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
78042.20 million40.59 millionOptionable
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
32036.67 million25.45 millionOptionable
Pulmonx Co. stock logo
LUNG
Pulmonx
25039.80 million37.24 millionOptionable

Recent News About These Companies

Brokerages Set Pulmonx Co. (NASDAQ:LUNG) Price Target at $13.36
Wildfires Take Toll on Respiratory Health
Pulmonx initiated with a Buy at D. Boral Capital
Lake Street Keeps Their Buy Rating on Pulmonx (LUNG)
Lake Street Keeps Their Buy Rating on Pulmonx (LUNG)
EDAP Appoints Glen French to Board of Directors
Citi Reaffirms Their Hold Rating on Pulmonx (LUNG)
Pulmonx management to meet virtually with Lake Street
Pulmonx (LUNG) Gets a Buy from Piper Sandler

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Atrion stock logo

Atrion NASDAQ:ATRI

Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmic applications in the United States, Canada, Europe, and internationally. The company's fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments. Its cardiovascular products comprise Myocardial Protection System that delivers fluids and medications, and mixes critical drugs, as well as controls temperature, pressure, and other variables; cardiac surgery vacuum relief valves; silicone vessel loops for retracting and occluding vessels; and inflation devices for balloon catheter dilation, stent deployment, and fluid dispensing, as well as products for use in heart bypass surgery. The company's ophthalmic products consist of a line of balloon catheters, which are used for the treatment of nasolacrimal duct obstruction in children and adults. It manufactures products for safe needle and scalpel blade containment; inflation systems and valves used in marine and aviation safety products; components used in inflatable survival products and structures; and one-way and two-way pressure relief valves that protect sensitive electronics and other products during transport in other medical and non-medical applications. The company sells its products to physicians, hospitals, clinics, and other treatment centers; and other equipment manufacturers through direct sales force, independent sales representatives, and distributors. Atrion Corporation was founded in 1944 and is headquartered in Allen, Texas.

Cardiovascular Systems stock logo

Cardiovascular Systems NASDAQ:CSII

Cardiovascular Systems, Inc. is a medical device company, which engages in the development and commercialization of solutions for treating vascular and coronary disease. It offers orbital atherectomy systems for both peripheral and coronary commercial applications. The company was founded in 1989 and is headquartered in St. Paul, MN.

Inovio Pharmaceuticals stock logo

Inovio Pharmaceuticals NASDAQ:INO

$1.52 -0.08 (-4.72%)
As of 12:27 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

Pulmonx stock logo

Pulmonx NASDAQ:LUNG

$5.26 -0.17 (-3.04%)
As of 12:27 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.